buy cialis
buy viagra
buy paxil
buy lipitor
buy propecia
buy celebrex
buy zoloft
buy accutane
buy prozac
buy cialis
buy viagra
buy prozac
buy kamagra
buy xenical
buy codeine
buy propecia
buy cialis
buy viagra
buy levitra
buy lexapro
buy propecia
buy tramadol
buy soma
buy accutane
buy prozac
NEW YORK (Reuters Health) - There's new advice for older men who want to preserve their sexual function: have sex, and have it often, researchers say.
In a study that followed nearly 1,000 older Finnish men for five years, researchers found that those who were regularly having sex at the start of the study were at lower risk of developing erectile dysfunction (Buy Viagra) by the study's end.
In fact, the more often the men had sex, the lower their Buy Generic Viagra risk.
The implication, say the researchers, is that men should be encouraged to stay sexually active into their golden years.
Dr. Juha Koskimaki and colleagues at the University of Tampere in Finland report the findings in the American Journal of Medicine. The study included 989 men who were between the ages of 55 and 75 at the outset.
Overall, those who said they had sex less than once per week were twice as likely to develop ED over the next five years as men who had sex at least once a week. Furthermore, compared with men who had sex three or more times per week, their Order Viagra risk was increased nearly four-fold.
A number of factors contribute to ED development, many of which could also affect a man's sexually activity -- such as age, diabetes and heart disease. However, after taking account of those factors, sexual activity itself remained linked to Cheap Viagra risk, Koskimaki's team found.
It may be a matter of "use it or lose it," according to the researchers. Just as exercise boosts physical fitness, they note, regular sexual activity may help a man preserve his erectile function.
buy viagra online occurs when there are problems with blood flow to the penis. Regular sexual activity, Koskimaki's team writes, may help maintain healthy blood vessel function in the erectile tissue.
SOURCE: American Journal of Medicine, July 2008.
Welcome to EBE, the Voice of Biopharmaceuticals in Europe
All stakeholders should stand to benefit from the advances in healthcare that biopharmaceutical technology offers and they all have a role to play. EBE has become a key focal point for information exchange between the research-based biopharmaceutical industry operating in Europe and all major stakeholders engaged in this process.
Biotechnology is delivering significant advances in human healthcare. Entirely new medicines are being created, notably for rare or previously untreated diseases. Biotech production methods provide safer versions of existing treatments in unlimited quantities. Biotechnology has revolutionised the research and development of new medicines and allows better product targeting for specific diseases and patient groups. A greater understanding of the genetic causes of disease allows early detection and treatment, and the new field of gene therapy may even herald the possibility to cure diseases, not simply treat them.
| Current Issues |
EBE Welcomes New EU Strategy and Communication on Rare Diseases EuropaBio and EBE congratulate EU leaders on the Commission Communication on Rare Diseases and calls for European action to turn principles and proposals into reality
more
| Call on EU leaders to improve access to orphan medicines for all EU patients EPPOSI organized its 9th workshop on Partnering for Rare Diseases Therapy Development.
Rare disease patients, academic researchers, NGOs and industry united their voices in a call to EU governments to take action this Autumn to address the issues facing patients affected by rare diseases in Europe. The need is urgent because, for some patients, time is short.
more
|
EBE Annual Highlights 2007-2008 EBE tells you why you should care about biotechnology in healthcare. Biotechnology is essential for medical progress and the quality of healthcare. It has created a new generation of therapeutics – the biopharmaceuticals – and has supplied powerful research tools for drug discovery and new in-vitro diagnostics.
more
| New EBE Publication on Benefit / Risk Balance: A Shared Responsibility The European Biopharmaceutical Enterprises association has initiated discussions on the benefit and risk balance of new therapies. EBE calls for a greater understanding of the roles played by the different stakeholders involved in the management of disease and the introduction of new medicines.
more
|
